NKT2152
Urologic Diseases
NiKang Therapeutics, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Urologic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rocuronium Rainer Lenhardt | Phase 4 | BB |
Zoladex University College, London | Phase 3 | BB |
LEUPROLIDE University College, London | Phase 3 | BB |
Casodex University College, London | Phase 3 | B |
Zoledronate Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 17 →
Same molecule, other indications
NKT2152 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →